Houston-based accelerator to provide platform for growth to early stage life sciences and biotech companies
HOUSTON, Sept. 24, 2019 /PRNewswire/ — Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused on the research, development and commercialization of new therapies and technologies in the expanding field of regenerative medicine.
https://houstonhealthspan.com/wp-content/uploads/2019/09/news-generic-lab-800x400.jpg400800Lee Ann Crainhttps://houstonhealthspan.com/wp-content/uploads/2019/09/HHIG-logo-v2.svgLee Ann Crain2019-09-24 13:02:232019-09-25 14:08:11Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development
New leading-edge technology produces higher yields of stem cells to enhance patient treatments
HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible.
https://houstonhealthspan.com/wp-content/uploads/2019/09/IcellatorX-delivers-results-08-21-19-720x405.jpg405720Lee Ann Crainhttps://houstonhealthspan.com/wp-content/uploads/2019/09/HHIG-logo-v2.svgLee Ann Crain2019-08-21 00:28:592019-09-12 00:31:17Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application
Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases
HOUSTON, May 29, 2019 — Rejenevie™ Therapeutics announced the commencement of the company’s Phase Ib clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration treatments targeting age-related diseases.
ATLANTA (April 1, 2019) – W.E. “Ed” Bosarge Jr., PhD gave remarks Monday, April 1st, at the American Association of Cancer Research’s annual meeting in Atlanta. He introduced this year’s recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research, Dr. Andrew T. Chan. Bosarge endows this $10,000 award given annually to an outstanding cancer researcher under the age of 51 who has conducted highly meritorious translational and clinical cancer research.
https://houstonhealthspan.com/wp-content/uploads/2019/04/Bosarge-Chan-AACR-2019-800x500.jpg500800Lee Ann Crainhttps://houstonhealthspan.com/wp-content/uploads/2019/09/HHIG-logo-v2.svgLee Ann Crain2019-04-01 00:36:172019-09-12 00:50:39Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the American Association of Cancer Research’s Annual Meeting
HOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. The 10-year agreement marks a major leap forward in advancing the field of regenerative medicine through state-of-the-art point-of-care platform technology, to meet the broad needs of a growing, global healthcare market.
https://houstonhealthspan.com/wp-content/uploads/2017/08/News-TG-icellator-720x405.jpg405720Lee Ann Crainhttps://houstonhealthspan.com/wp-content/uploads/2019/09/HHIG-logo-v2.svgLee Ann Crain2017-08-01 07:24:022019-09-12 07:50:35TG & Human Life CORD, Japan Announce Exclusive Partnership
Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development
/in News /by Lee Ann CrainHouston-based accelerator to provide platform for growth to early stage life sciences and biotech companies
HOUSTON, Sept. 24, 2019 /PRNewswire/ — Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused on the research, development and commercialization of new therapies and technologies in the expanding field of regenerative medicine.
Read more
Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application
/in News /by Lee Ann CrainNew leading-edge technology produces higher yields of stem cells to enhance patient treatments
HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible.
Read more
Rejenevie™ Therapeutics Announces Start of Phase Ib Immune Restoration Treatment Clinical Trial
/in News /by Lee Ann CrainPromising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases
HOUSTON, May 29, 2019 — Rejenevie™ Therapeutics announced the commencement of the company’s Phase Ib clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration treatments targeting age-related diseases.
Read more
Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the American Association of Cancer Research’s Annual Meeting
/in News /by Lee Ann CrainATLANTA (April 1, 2019) – W.E. “Ed” Bosarge Jr., PhD gave remarks Monday, April 1st, at the American Association of Cancer Research’s annual meeting in Atlanta. He introduced this year’s recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research, Dr. Andrew T. Chan. Bosarge endows this $10,000 award given annually to an outstanding cancer researcher under the age of 51 who has conducted highly meritorious translational and clinical cancer research.
Read more
TG & Human Life CORD, Japan Announce Exclusive Partnership
/in News /by Lee Ann CrainHOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. The 10-year agreement marks a major leap forward in advancing the field of regenerative medicine through state-of-the-art point-of-care platform technology, to meet the broad needs of a growing, global healthcare market.
Read more